Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Aerovate Therapeutics Inc (NQ: AVTE )

1.905 -0.005 (-0.25%)
Streaming Delayed Price Updated: 9:34 AM EDT, Sep 19, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Aerovate Therapeutics Inc

< Previous 1 2 3 4 Next >
AVTE Stock Earnings: Aerovate Therapeutics Misses EPS for Q2 2024
AVTE stock results show that Aerovate Therapeutics missed analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
Aerovate Therapeutics to Explore Strategic Alternatives
From Aerovate Therapeutics, Inc.
Via GlobeNewswire
The 3 Hottest Stock Downgrades From Last Week
Explore the experts' latest surprising stock downgrades amid significant market shifts and analyst adjustments. 
Via InvestorPlace
Nasdaq Surges Over 200 Points; Aaron's Shares Jump
Via Benzinga
Why Ovid Therapeutics Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Crude Oil Rises 1%; Mustang Bio Shares Spike Higher
Via Benzinga
Exposures Fossil Fuels
Why 90% Of Aerovate Therapeutics' Value Just Went Up In Smoke
The company was working on a treatment for pulmonary arterial hypertension, a form of high blood pressure in the lungs. 
Via Investor's Business Daily
Why Is Small Cap-Heart Disease Focused Aerovate Therapeutics Stock Plummeting On Monday?
Aerovate Therapeutics shares dropped 90.4% following the release of Phase 2b trial results for AV-101 for pulmonary arterial hypertension. Despite being well tolerated, AV-101 failed to meet primary... 
Via Benzinga
US Stocks Mixed; Dow Tumbles Over 100 Points
Via Benzinga
Topics Stocks
Exposures US Equities
Recap: Aerovate Therapeutics Q4 Earnings
Via Benzinga
Recap: Aerovate Therapeutics Q3 Earnings
Via Benzinga
Recap: Aerovate Therapeutics Q1 Earnings
Via Benzinga
Aerovate Therapeutics Announces 24-Week Topline Results from the Phase 2b Portion of IMPAHCT Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension
AV-101 did not meet the primary endpoint of change in pulmonary vascular resistance (PVR) for any of the studied doses 
From Aerovate Therapeutics, Inc.
Via GlobeNewswire
Aerovate Therapeutics Presents Baseline Data from the Phase 2b Portion of the IMPAHCT Trial at the American Thoracic Society 2024 International Conference
From Aerovate Therapeutics, Inc.
Via GlobeNewswire
AVTE Stock Earnings: Aerovate Therapeutics Misses EPS for Q1 2024
AVTE stock results show that Aerovate Therapeutics missed analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
Aerovate Therapeutics Announces First Quarter Financial Results and Business Highlights
From Aerovate Therapeutics, Inc.
Via GlobeNewswire
Ermenegildo Zegna Reports FY23 Results, Joins Altice USA, Herbalife And Other Big Stocks Moving Lower On Friday
U.S. stocks were higher, with the Nasdaq Composite gaining over 100 points on Friday. Shares of Ermenegildo Zegna N.V. (NYSE: ZGN) fell sharply during Friday’s session as the company reported FY23... 
Via Benzinga
Topics Stocks
Exposures US Equities
Aerovate Therapeutics to Present Patient Baseline Characteristics of the Phase 2b Portion of the Phase 2b/Phase 3 IMPAHCT Trial at the American Thoracic Society 2024 International Conference
From Aerovate Therapeutics, Inc.
Via GlobeNewswire
AVTE Stock Earnings: Aerovate Therapeutics Misses EPS for Q4 2023
AVTE stock results show that Aerovate Therapeutics missed analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
Aerovate Therapeutics Announces Full-Year 2023 Financial Results and Business Highlights
From Aerovate Therapeutics, Inc.
Via GlobeNewswire
Aerovate Therapeutics Board of Directors Appoints Habib Dable as Board Chair
From Aerovate Therapeutics, Inc.
Via GlobeNewswire
Aerovate Therapeutics Announces Simultaneous Completion of Enrollment in Phase 2b Portion and Enrollment of First Patient into Phase 3 in the IMPAHCT Trial Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension
From Aerovate Therapeutics, Inc.
Via GlobeNewswire
Aerovate Therapeutics Announces Third Quarter Financial Results and Business Highlights
From Aerovate Therapeutics, Inc.
Via GlobeNewswire
Aerovate Therapeutics Announces Second Quarter Financial Results and Business Highlights
From Aerovate Therapeutics, Inc.
Via GlobeNewswire
Aerovate Therapeutics Appoints Habib Dable To Its Board of Directors
From Aerovate Therapeutics, Inc.
Via GlobeNewswire
Aerovate Therapeutics to Present at Jefferies Global Healthcare Conference
From Aerovate Therapeutics, Inc.
Via GlobeNewswire
Aerovate Therapeutics Presents Nonclinical Pharmacokinetic Data in Support of AV-101, a Novel Dry Powder Inhaled Formulation of Imatinib, at the American Thoracic Society (ATS) 2023 International Conference
From Aerovate Therapeutics, Inc.
Via GlobeNewswire
Aerovate Therapeutics Announces First Quarter Financial Results and Business Highlights
From Aerovate Therapeutics, Inc.
Via GlobeNewswire
Aerovate Therapeutics Announces Full-Year 2022 Financial Results and Business Highlights
From Aerovate Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.